BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and Monogram Biosciences, Inc., part of the LabCorp Specialty Testing Group, today announced the launch of HIV GenoSure ArchiveSM, the first laboratory test to help optimize antiretroviral (ARV) drug regimens in virally suppressed HIV patients. GenoSure Archive was developed using the Next Generation Sequencing (NGS) platform.
Advances in HIV drug therapy have allowed patients to achieve and maintain complete suppression of viral replication. Life-long treatment, however, is necessary to maintain viral suppression. Such treatment therapies often have adverse side effects, and as new, more simplified ARV drug regimens become available, patients may benefit from new therapies. Previous laboratory testing to guide ARV drug selection required higher viral loads than what many patients have, leaving clinicians without a reliable diagnostic tool to guide ongoing therapy choices. HIV GenoSure Archive is the first genotypic drug resistance assay specifically designed to reliably identify the HIV DNA compartment, and it provides physicians and other HIV care providers with critical diagnostic information to support individualized and updated therapies for patients with low or undetectable viral loads of HIV-1.
Help employers find you! Check out all the jobs and post your resume.
